HIGHLIGHTS
- who: Tarek, Mekhail and Maurice, Pu00e9rol from the David Geffen School of Medicine at UCLA/TRIO-US Network, Santa Monica, CA, USA have published the Article: Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study, in the Journal: (JOURNAL)
- what: This analysis examined HCRU among the ITT population and subgroups of patients with aggressive aNSCLC from the REVEL study.
- how: Considered together the results suggest that the survival benefit and manageable safety profile provided by the addition of ramucirumab to docetaxel as . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.